Great progress has been made over the past half-century, but TB remains a formidable
global health problem, particularly in low-and middle-income countries. Understanding the …

Background Tuberculosis (TB) is a global health challenge and one of the leading causes of
death worldwide. In the last decade, the TB treatment landscape has dramatically changed …

Background In patients with rifampin-resistant tuberculosis, all-oral treatment regimens that
are more effective, shorter, and have a more acceptable side-effect profile than current …

Background Tuberculosis is usually treated with a 6-month rifampin-based regimen.
Whether a strategy involving shorter initial treatment may lead to similar outcomes is …

The WHO Consolidated Guidelines on Tuberculosis (TB), Module 4: Treatment-Drug-
Resistant Tuberculosis Treatment 2022 update informs health care professionals in Member …

Background The STREAM stage 1 trial showed that a 9-month regimen for the treatment of
rifampicin-resistant tuberculosis was non-inferior to the 20-month 2011 WHO-recommended …

Multidrug-resistant tuberculosis (MDR-TB) is among the most frequent causes of death due
to antimicrobial resistance. Although only 3% of global TB cases are MDR, geographical …

Our current treatment regimen for tuberculosis, which goes by the somewhat ironic name of
“directly observed therapy, short course,” is anything but short. Patients are treated …

Tuberculosis (TB) elimination and pre-elimination, with thresholds of 1 and 10 incident
cases per million population, respectively, were considered achievable for low TB incidence …

Although COVID-19 has undermined global progress, many African countries have
sustained declines in tuberculosis mortality rates. With excellent short-course preventive …